ERBB2 and breast cancer: Mostly based on data from the SOPHIA trial (NCT02492711), in 2020, the FDA approved its use in combination with chemotherapy for the treatment of metastatic HER2 BC patients who have received at least two previous anti-HER2 therapies [88].